A Phase 1 interventional study of Placebo and XTMAB-16 2 mg/kg in Healthy Participants, sponsored by Xentria, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-14.
Sponsored by Xentria, Inc. · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a single-center, randomized, double-blind, placebo-controlled, first-in-human, single intravenous (IV) infusion of XTMAB-16 (formerly referred to as KBMAB-16) in normal healthy male and female participants.
A total of 24 normal healthy adult participants will be enrolled and assigned into 2 treatment cohorts with 12 participants (9 on XTMAB-16 and 3 on placebo) in each cohort. Participants will receive a single IV infusion of 2 mg/kg or 4 mg/kg of XTMAB-16 or placebo on Day 1.
Xentria, Inc. is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single IV Infusion
Drug: Placebo
Single IV Infusion
Drug: XTMAB-16 2 mg/kg
Single IV Infusion
Drug: XTMAB-16 4mg/kg
Single dose of 2 or 4 mg/kg
Single dose of 2 mg/kg
Single dose of 4 mg/kg
Participant With Treatment Emergent Adverse Events (TEAEs)
Treatment-emergent adverse event, which is an undesirable event that occurs during or shortly after treatment begins.
Time frame: Up to day 71
Participants by Cohort Who Test Positive for XTMAB-16 Anti-drug Antibody (ADA)
Participants by cohort who test positive for XTMAB-16 ADA
Time frame: ADA and nAB: Days 1, 8, 15, 29, 43, 57, 71
Participants by Cohort Who Test Positive for XTMAB-16 Neutralizing Antibody (nAb)
Participants by cohort who test positive for XTMAB-16 nAb
Time frame: ADA and nAB: Days 1, 8, 15, 29, 43, 57, 71
XTMAB-16 Maximum Observed Concentration (Cmax)
XTMAB-16 (Cmax)
Time frame: Up to day 71
XTMAB-16 Serum Observed Plasma Concentration at the End of Infusion (CT) Day 1
XTMAB-16 serum (CT) Day 1
Time frame: Day 1
Time to Maximum Observed Concentration (Tmax) XTMAB-16
Time to maximum observed concentration (tmax) XTMAB-16
Time frame: PK: Days 1, 2, 3, 4, 8, 15, 29, 43, 57, 71
Area Under the XTMAB-16 Concentration-time Curve From Time Zero (Predose) Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞)
Area under the XTMAB-16 concentration-time curve from time zero (predose) AUC0-∞
Time frame: PK: Days 1, 2, 3, 4, 8, 15, 29, 43, 57, 71
Area Under the XTMAB-16 Concentration-time-curve From Time Zero to (Predose) Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t)
Area under the XTMAB-16 concentration-time-curve from time zero to (predose) AUC0-t
Time frame: PK: Days 1, 2, 3, 4, 8, 15, 29, 43, 57, 71
Systemic Clearance After IV Dosing (CL)
Systemic clearance after IV dosing (CL)
Time frame: Up to day 71
Apparent Terminal Half-life (t1/2)
Time frame: Up to day 71
Volume of Distribution Following IV Dosing (Vz) Day 1 up to Day 71
Time frame: Up to day 71
Mean Residence Time (MRT)
Mean residence time (MRT)
Time frame: Up to day 71
| Milestone | Pooled Placebo | Single IV Infusion of 2 mg/kg of XTMAB-16 | Single IV Infusion of 4 mg/kg of XTMAB-16 |
|---|---|---|---|
| Started | 6 | 10 | 9 |
| Completed | 6 | 9 | 9 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
Treatment-emergent adverse event, which is an undesirable event that occurs during or shortly after treatment begins.
| Participants | 2 mg/kg XTMAB-16 | 4 mg/kg XTMAB-16 | Pooled Placebo |
|---|---|---|---|
| Participant With Treatment Emergent Adverse Events (TEAEs) | 2 | 3 | 1 |
Participants by cohort who test positive for XTMAB-16 ADA
| Participants | 2 mg/kg XTMAB-16 | 4 mg/kg XTMAB-16 | Pooled Placebo |
|---|---|---|---|
| Day 1 ADA Screening | 0 | 0 | 0 |
| Day 8 ADA Screening | 0 | 0 | 0 |
| Day 15 ADA Screening | 1 | 1 | 0 |
| Day 15 ADA Confirmatory | 0 | 0 | 0 |
| Day 29 ADA Screening | 1 | 0 | 0 |
| Day 29 ADA Confirmatory | 1 | 0 | 0 |
| Day 43 ADA Screening | 4 | 0 | 0 |
| Day 43 ADA Confirmatory | 3 | 0 | 0 |
| Day 57 ADA Screening | 6 | 1 | 0 |
| Day 57 ADA Confirmatory | 5 | 1 | 0 |
| Day 71 ADA Screening | 6 | 3 | 0 |
| Day 71 ADA Confirmatory | 6 | 2 | 0 |
Participants by cohort who test positive for XTMAB-16 nAb
| Participants | 2 mg/kg XTMAB-16 | 4 mg/kg XTMAB-16 | Pooled Placebo |
|---|---|---|---|
| Day 29 | 1 | 0 | 0 |
| Day 43 | 3 | 0 | 0 |
| Day 57 | 5 | 1 | 0 |
| Day 71 | 6 | 2 | 0 |
XTMAB-16 (Cmax)
| Cmax (μg/mL) | 2 mg/kg XTMAB-16 | 4 mg/kg XTMAB-16 |
|---|---|---|
| XTMAB-16 Maximum Observed Concentration (Cmax) | 64.17 ± 9.94 | 131 ± 23.42 |
XTMAB-16 serum (CT) Day 1
| CT (μg/mL) | 2 mg/kg XTMAB-16 | 4 mg/kg XTMAB-16 |
|---|---|---|
| XTMAB-16 Serum Observed Plasma Concentration at the End of Infusion (CT) Day 1 | 62.18 ± 6.757 | 128.9 ± 22.39 |
Time to maximum observed concentration (tmax) XTMAB-16
| tmax (h) | 2 mg/kg XTMAB-16 | 4 mg/kg XTMAB-16 |
|---|---|---|
| Time to Maximum Observed Concentration (Tmax) XTMAB-16 | 2.16 (2.1 to 8.65) | 3.0 (2.12 to 8.02) |
Area under the XTMAB-16 concentration-time curve from time zero (predose) AUC0-∞
| AUC0-inf (day*μg/mL) | 2 mg/kg XTMAB-16 | 4 mg/kg XTMAB-16 |
|---|---|---|
| Area Under the XTMAB-16 Concentration-time Curve From Time Zero (Predose) Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) | 601.5 ± 231.8 | 1249 ± 245.0 |
Area under the XTMAB-16 concentration-time-curve from time zero to (predose) AUC0-t
| AUC0-last (day*μg/mL) | 2 mg/kg XTMAB-16 | 4 mg/kg XTMAB-16 |
|---|---|---|
| Area Under the XTMAB-16 Concentration-time-curve From Time Zero to (Predose) Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t) | 525.2 ± 238.0 | 1224 ± 235.9 |
Systemic clearance after IV dosing (CL)
| CL (L/day) | 2 mg/kg XTMAB-16 | 4 mg/kg XTMAB-16 |
|---|---|---|
| Systemic Clearance After IV Dosing (CL) | 0.2498 ± 0.04883 | 0.2449 ± 0.06064 |
| t1/2 (day) | 2 mg/kg XTMAB-16 | 4 mg/kg XTMAB-16 |
|---|---|---|
| Apparent Terminal Half-life (t1/2) | 8.644 ± 4.726 | 10.23 ± 3.617 |
| Vz (L) | 2 mg/kg XTMAB-16 | 4 mg/kg XTMAB-16 |
|---|---|---|
| Volume of Distribution Following IV Dosing (Vz) Day 1 up to Day 71 | 2.864 ± 0.8861 | 3.435 ± 0.9878 |
Mean residence time (MRT)
| MRT (day) | 2 mg/kg XTMAB-16 | 4 mg/kg XTMAB-16 |
|---|---|---|
| Mean Residence Time (MRT) | 12.51 ± 6.214 | 13.32 ± 3.794 |
Collected over The Investigator or designee recorded all reportable events with start dates occurring from informed consent until 7 (for nonserious AEs) or 30 days (for SAEs) after the last day of study participation. Study participation was up to 71 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 2 mg/kg XTMAB-16 | 0/10 (0%) | 0/10 (0%) | 3/10 (30%) |
| 4 mg/kg XTMAB-16 | 0/9 (0%) | 1/9 (11.1%) | 4/9 (44.4%) |
| Pooled Placebo | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Event | 2 mg/kg XTMAB-16 | 4 mg/kg XTMAB-16 | Pooled Placebo |
|---|---|---|---|
| abdominal painGastrointestinal disorders | 0/10 | 1/9 | 0/6 |
| Event | 2 mg/kg XTMAB-16 | 4 mg/kg XTMAB-16 | Pooled Placebo |
|---|---|---|---|
| HeadacheNervous system disorders | 1/10 | 2/9 | 0/6 |
| Abdominal PainGastrointestinal disorders | 0/10 | 2/9 | 0/6 |
| Nasal CongestionRespiratory, thoracic and mediastinal disorders | 0/10 | 2/9 | 0/6 |
| Dry MouthGastrointestinal disorders | 0/10 | 1/9 | 1/6 |
| Eye Pain due to Covid TestingEye disorders | 0/10 | 0/9 | 1/6 |
| FatigueGeneral disorders | 1/10 | 1/9 | 0/6 |
| Decreased AppetiteMetabolism and nutrition disorders | 1/10 | 1/9 | 0/6 |
| BloatingGastrointestinal disorders | 0/10 | 1/9 | 0/6 |
| ConstipationGastrointestinal disorders | 0/10 | 1/9 | 0/6 |
| DehydrationMetabolism and nutrition disorders | 0/10 | 1/9 | 0/6 |
| Age, Categorical(Participants) | Single IV Infusion of 2 mg/kg of XTMAB-16 | Single IV Infusion of 4 mg/kg of XTMAB-16 | Pooled Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 10 | 9 | 6 | 25 |
| >=65 years | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Single IV Infusion of 2 mg/kg of XTMAB-16 | Single IV Infusion of 4 mg/kg of XTMAB-16 | Pooled Placebo | Total |
|---|---|---|---|---|
| Female | 7 | 6 | 3 | 16 |
| Male | 3 | 3 | 3 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Single IV Infusion of 2 mg/kg of XTMAB-16 | Single IV Infusion of 4 mg/kg of XTMAB-16 | Pooled Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 2 | 6 |
| Not Hispanic or Latino | 8 | 7 | 4 | 19 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Single IV Infusion of 2 mg/kg of XTMAB-16 | Single IV Infusion of 4 mg/kg of XTMAB-16 | Pooled Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 8 | 8 | 4 | 20 |
| White | 1 | 1 | 2 | 4 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jun 2021 to primary completion in Mar 2022, 8 months.
Results were first posted in Jan 2025, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xentria, Inc.